WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 558246
Description: T-0632 is a novel potent and selective CCKA receptor antagonist.
MedKoo Cat#: 558246
Chemical Formula: C29H27FN2O5
Exact Mass: 502.1904
Molecular Weight: 502.54
Elemental Analysis: C, 69.31; H, 5.42; F, 3.78; N, 5.57; O, 15.92
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: T-0632, T 0632, T0632
IUPAC/Chemical Name: 3-[(3S)-1-(2-fluorophenyl)-6-methoxy-2-oxo-3-(1,2,3,4-tetrahydronaphthalene-2-carbonylamino)indol-3-yl]propanoic acid
InChi Key: RORYEMYJJAIHBK-PRTIIRGTSA-N
InChi Code: InChI=1S/C29H27FN2O5/c1-37-21-12-13-22-25(17-21)32(24-9-5-4-8-23(24)30)28(36)29(22,15-14-26(33)34)31-27(35)20-11-10-18-6-2-3-7-19(18)16-20/h2-9,12-13,17,20H,10-11,14-16H2,1H3,(H,31,35)(H,33,34)/t20?,29-/m0/s1
SMILES Code: O=C(O)CC[C@@]1(NC(C2CC3=C(C=CC=C3)CC2)=O)C(N(C4=CC=CC=C4F)C5=C1C=CC(OC)=C5)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 502.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Tibaduiza EC, Chen C, Beinborn M. A small molecule ligand of the glucagon-like peptide 1 receptor targets its amino-terminal hormone binding domain. J Biol Chem. 2001 Oct 12;276(41):37787-93. Epub 2001 Aug 9. PubMed PMID: 11498540.
2: Dong M, Vattelana AM, Lam PC, Orry AJ, Abagyan R, Christopoulos A, Sexton PM, Haines DR, Miller LJ. Development of a highly selective allosteric antagonist radioligand for the type 1 cholecystokinin receptor and elucidation of its molecular basis of binding. Mol Pharmacol. 2015 Jan;87(1):130-40. doi: 10.1124/mol.114.095430. Epub 2014 Oct 15. PubMed PMID: 25319540; PubMed Central PMCID: PMC4279081.
3: Niederau C, Grendell JH. Role of cholecystokinin in the development and progression of acute pancreatitis and the potential of therapeutic application of cholecystokinin receptor antagonists. Digestion. 1999;60 Suppl 1:69-74. PubMed PMID: 10026436.
4: Taniguchi H, Yomota E, Kume E, Shikano T, Endo T, Nagasaki M. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol. 1997 Feb;73(2):105-12. PubMed PMID: 9074944.